International Severe Asthma Registry: Canadian Cohort
Launched by UNIVERSITY OF BRITISH COLUMBIA · Aug 2, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The International Severe Asthma Registry: Canadian Cohort is a study that aims to improve the care of people with severe asthma by collecting important health information from participants across Canada. This registry will track individuals with severe asthma over five years to see how well they respond to different treatments. By gathering this data, researchers hope to better understand severe asthma and develop more effective care options for those living with this condition.
To participate in this study, individuals must be 18 years or older and either be receiving the highest level of asthma treatment (called GINA Step 5) or have uncontrolled asthma symptoms while on a slightly lower level of treatment (GINA Step 4). Unfortunately, those with mild to moderate asthma are not eligible. Participants can expect to provide information about their asthma and treatment over the course of the study, which will help improve the understanding and management of severe asthma in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants 18 years or older
- • Participants receiving treatment according to GINA Step 5 or uncontrolled in GINA Step 4 (uncontrolled is defined as having severe asthma symptoms or frequent exacerbations)
- Exclusion Criteria:
- • -Participants with mild to moderate asthma
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kingston, Ontario, Canada
Saskatoon, Saskatchewan, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Sherbrooke, Quebec, Canada
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Montréal, Quebec, Canada
Toronto, Ontario, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Quebéc City, Quebec, Canada
Patients applied
Trial Officials
Celine Bergeron
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials